Announcements Trials
Browse Landscape

Phase

Phase 1 8Phase 2 3Phase 1/2 3

Status

Terminated 2Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Thoracic 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Leukemia 33Leukemia, Myeloid, Acute 31Leukemia, Lymphocytic, Chronic, B-Cell 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Myelodysplastic Syndromes 18Lymphoma, Non-Hodgkin 18Lymphoma 17Hodgkin Disease 16Multiple Myeloma 12Lymphoma, Mantle-Cell 11Recurrence 10Melanoma 10Lymphoma, Large B-Cell, Diffuse 10Lymphoma, Follicular 10Lymphoma, B-Cell, Marginal Zone 10Leukemia, Myelomonocytic, Chronic 10Burkitt Lymphoma 10Waldenstrom Macroglobulinemia 8Neoplasms, Plasma Cell 8Neoplasm Metastasis 8Myeloproliferative Disorders 8Leukemia, Myeloid, Accelerated Phase 8Lymphoma, Large-Cell, Immunoblastic 7Leukemia, Myeloid, Chronic-Phase 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Leukemia, Biphenotypic, Acute 7Hematologic Neoplasms 7Congenital Abnormalities 7Lymphoma, T-Cell, Cutaneous 6Lymphoma, B-Cell 6

Interventions

Carboplatin 46Paclitaxel 31pembrolizumab 25Cyclophosphamide 24Nivolumab 14Bevacizumab 14Topotecan 12Gemcitabine 12liposomal doxorubicin 11Filgrastim 11Cisplatin 11fludarabine 10Peripheral Blood Stem Cell Transplantation 10olaparib 8aldesleukin 7durvalumab 6Oxaliplatin 6Ipilimumab 6Interleukin-2 6Docetaxel 6niraparib 5epacadostat 5cemiplimab 5Ifosfamide 5Fulvestrant 5rucaparib 4poly ICLC 4pazopanib 4avelumab 4atezolizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Ovarian Neoplasms × fludarabine phosphate × Clear all
NCT04611126 2025-08-12

T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer

Herlev Hospital

Phase 1/2 Terminated
6 enrolled 11 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03287674 2023-03-01

TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer

Herlev Hospital

Phase 1/2 Completed
7 enrolled 10 charts
Gynecologic

Ovarian Neoplasms

NCT01583686 2019-10-14

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
15 enrolled 14 charts
GastrointestinalGynecologicOther solid neoplasmThoracic

Uterine Cervical Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡